Dose escalation in intrathecal baclofen therapy based on disease etiology: Can an a priori target dose be established? A ten-year follow-up study

References

• Lance JW. Spasticity: disordered motor control. In: Feldman RG, Young RR, Koella WP, (eds.) Symposium synopsis. Chicago, IL: Yearbook Medical; 1980. p. 485–494.
   Google Scholar
• Langerak NG, Lamberts RP, Fieggen AG, Peter JC, Peacock WJ, Vaughan CL. Selective dorsal rhizotomy: long-term experience from Cape Town. Childs Nerv Syst 2007;23:1003–1006. doi:10.1007/s00381-007-0383-9.
   PubMed Web of Science ®Google Scholar
• Bolster EA, van Schie PE, Becher JG, Van Ouwerkerk WJ, Strijers RL, Vermeulen RJ. Long-term effect of selective dorsal rhizotomy on gross motor function in ambulant children with spastic bilateral cerebral palsy, compared with reference centiles. Dev Med Child Neurol 2013;55:610–616. doi:10.1111/dmcn.12148.
   PubMed Web of Science ®Google Scholar
• Aquilina K, Graham D, Wimalasundera N. Selective dorsal rhizotomy: an old treatment re-emerging. Arch Dis Child 2015;100:798–802. doi:10.1136/archdischild-2014-306874.
   PubMed Web of Science ®Google Scholar
• Pert CB, Kuhar MJ, Snyder SH. Autoradiographic localization of the opiate receptor in rat brain. Life Sci 1975;16:1849–1853. doi:10.1073/pnas.73.10.3729.
   PubMed Web of Science ®Google Scholar
• Penn RD, Kroin JS. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984;1(8385):6. doi:10.1016/s0140-6736(84)91487-9.
   Web of Science ®Google Scholar
• Bottros MM, Christo PJ. Current perspectives on intrathecal drug delivery. J Pain Res 2014;7:615–626. doi:10.2147/JPR.S37591.
   PubMed Web of Science ®Google Scholar
• Ashworth B, Grimby L, Kugelberg E. Comparison of voluntary and reflex activation of motor units. Functional organization of motor neurones. J Neurol Neurosurg Psychiatry 1967;30(2):91–98. doi:10.1136/jnnp.30.2.91.
   PubMed Web of Science ®Google Scholar
• Kawano O, Masuda M, Takao T, Sakai H, Morishita Y, Hayashi T, Ueta T, et al. The dosage and administration of long-term intrathecal baclofen therapy for severe spasticity of spinal origin. Spinal Cord 2018;56:996–999. doi:10.1038/s41393-018-0153-4.
   PubMed Web of Science ®Google Scholar
• Draulans N, Vermeersch K, Degraeuwe B, Meurrens T, Peers K, Nuttin B, Kiekens C. Intrathecal baclofen in multiple sclerosis and spinal cord injury: complications and long-term dosage evolution. Clin Rehabil 2013;27(12):1137–1143. doi:10.1177/0269215513488607.
   PubMed Web of Science ®Google Scholar
• Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS. Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 2004;75(11):1553–1557. doi:10.1136/jnnp.2003.014282.
   PubMed Web of Science ®Google Scholar
• Plassat R, Perrouin Verbe B, Menei P, Menegalli D, Mathe JF, Richard I. Treatment of spasticity with intrathecal Baclofen administration: long-term follow-up, review of 40 patients. Spinal Cord 2004;42:686–693. doi:10.1038/sj.sc.3101647.
   PubMed Web of Science ®Google Scholar
• Mathur SN, Chu SK, McCormick Z, Chien GC, Marciniak CM. Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. PM&R 2014;6(6):506–513. doi:10.1016/j.pmrj.2013.12.005.
   Web of Science ®Google Scholar
• Rekand T, Grønning M. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med 2011;43(6):511–514. doi:10.2340/16501977-0811.
   PubMed Web of Science ®Google Scholar
• Boster AL, Adair RL, Gooch JL, Nelson ME, Toomer A, Urquidez J, Saulino M. Best practices for intrathecal baclofen therapy: dosing and long-term management. Neuromodulation 2016;19(6):623–631. doi:10.1111/ner.12388.
   PubMed Web of Science ®Google Scholar
• Koulousakis A, Kuchta J. Intrathecal antispastic drug application with implantable pumps: results of a 10 year follow-up study. In: Sakas DE, Simpson BA, Krames ES, (eds.) Operative neuromodulation. Acta Neurochirurgica Supplements 97(1). Vienna, Austria: Springer; 2007. p. 184–188. doi:10.1007/978-3-211-33079-1_24.
   Google Scholar
• Stokic DS, Yablon SA. Neurophysiological basis and clinical applications of the H-reflex as an adjunct for evaluating response to intrathecal baclofen for spasticity. In: Sakas DE, Simpson BA, Krames ES, (eds.) Operative neuromodulation. Acta Neurochirurgica Supplements 97(1). Vienna, Austria: Springer; 2007. p. 231–241. doi:10.1007/978-3-211-33079-1_32.
   Google Scholar
• Sammaraiee Y, Yardley M, Keenan L, Buchanan K, Stevenson V, Farrell R. Intrathecal baclofen for multiple sclerosis related spasticity: a twenty year experience. Mult Scler Relat Disord 2019;27:95–100. doi:10.1016/j.msard.2018.10.009.
   PubMed Web of Science ®Google Scholar
• Stampacchia G, Gerini A, Mazzoleni S. Effects of severe spasticity treatment with intrathecal baclofen in multiple sclerosis patients: long term follow-up. NeuroRehabilitation 2016;38(4):385–393. doi:10.3233/NRE-161329.
   PubMed Web of Science ®Google Scholar
• Reis PV, Vieira CR, Midões AC, Rebelo V, Barbosa P, Gomes A. Intrathecal baclofen infusion pumps in the treatment of spasticity: a retrospective cohort study in a Portuguese centre. Acta Med Port 2019;32(12):754–759. doi:10.20344/amp.10482.
   PubMed Web of Science ®Google Scholar
• Natale M, Mirone G, Rotondo M, Moraci A. Intrathecal baclofen therapy for severe spasticity: analysis on a series of 112 consecutive patients and future perspectives. Clin Neurol Neurosurg 2012;114(4):321–325. doi:10.1016/j.clineuro.2011.10.046.
   PubMed Web of Science ®Google Scholar
• Boster AL, Adair RL, Gooch JL, Nelson ME, Toomer A, Urquidez J, Saulino M. Best practices for intrathecal baclofen therapy: dosing and long-term management. Neuromodulation 2016;19(6):623–631. doi:10.1111/ner.12388.
   PubMed Web of Science ®Google Scholar